AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20969443
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) using an InGaAlP diode laser, emitting light at 660 nm, 40 mW, and 4 J/cm².
Trial: 27869476
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LLLT treatment).
Trial: 9725475
Drug: Slow-release amitriptyline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release amitriptyline formulation
Trial: 8067694
Drug: 5-Fluorouracil (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Fluorouracil (1000 mg/m2 B.S.A. x 5 days) and Mitomycin‐C (14 mg/m2 B.S.A. 6 week intervals)
Trial: 8067694
Drug: 5-Fluorouracil (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Fluorouracil (750 mg/m2 B.S.A. x 5 days) and a‐Interferon (5 miu/m2 B.S.A. daily x 5 then 3 times a week (TIW))
Trial: 8067694
Drug: 5-Fluorouracil (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Fluorouracil (500 mg/m2 B.S.A. x 5 days), a‐Interferon (5 miu/m2 B.S.A. x 5 days then TIW) and 13‐Cis Retinoic Acid in escalating doses daily
Trial: 29733447
Drug: Verinurad 10
RxNorm normalized name: Verinurad
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad 10 mg + Allopurinol 300 mg
Trial: 29688628
Drug: Verinurad 10
RxNorm normalized name: Verinurad
DrugBank: Verinurad (DB11873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verinurad 10 mg
Trial: 29733447
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Verinurad and Allopurinol
Trial: 23653013
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment (intra-muscular testosterone administered every 14 days to achieve BT levels 70-270 ng/dL)
Trial: 23653013
Drug: Placebo (sesame
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sesame seed oil administered every 14 days)
Trial: 20439641
Drug: Rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab maintenance treatment (375 mg/m² intravenously once every 3 months)
Trial: 26132314
Drug: Rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab maintenance treatment
Trial: 16295040
Drug: HS-1 (Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-1 (Barrier Cream)
Trial: 16295040
Drug: HS-2 (Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-2 (Barrier Cream)
Trial: 10756492
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg buserelin (BSRL) stimulation (PCOD group P-1, n = 31)
Trial: 10756492
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg buserelin (BSRL) stimulation (PCOD group P-0.1, n = 12)
Trial: 1504957
Drug: Concentric Circle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentric Circle (CC) palpation technique
Trial: 6388898
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant human tissue-type plasminogen activator (rt-PA) at a dosage of 0.5 to 0.75 mg/kg over 30 to 120 min.
Trial: 6388898
Drug: Intracoronary streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary streptokinase (after unresponsive rt-PA treatment)
Trial: 29738412
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (oCEE and tE2 combined)
Trial: 18076234
Drug: Daily undulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily undulating periodization (n = 10)
Trial: 18076234
Drug: Weekly undulating
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly undulating periodization (n = 9)
Trial: 12366698
Drug: Naltrexone (NAL)
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone (NAL) 25 mg (Nemexin)
Trial: 7641913
Drug: Low-dose GnRH
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose GnRH agonist (GnRH-a) and hMG therapy
Trial: 7641913
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) and hMG therapy
Trial: 791468
Drug: Propranolol (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (long-term therapy)
Trial: 21272190
Drug: 6 mg/day
RxNorm normalized name: EMSAM 6 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/day MK-0916
Trial: 21272190
Drug: MK-0916 (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0916 (0.5, 2, or 6 mg/day)
Trial: 18001406
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg daily (EAC group, n = 209)
Trial: 18001406
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg b.i.d. (RAC group, n = 211)
Trial: 18001406
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg daily (EAC group)
Trial: 18001406
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg b.i.d. (RAC group)
Trial: 9219866
Drug: Pindolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (10 mg p.o.)
Trial: 15013031
Drug: Pindolol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (30 mg p.o.)
Trial: 9219866
Drug: Betaxolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol (20 mg p.o.)
Trial: 8396085
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg daily for three days
Trial: 8396085
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg bid for ten days
Trial: 26484794
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of glimepiride and atorvastatin (once daily for 20 weeks)
Trial: 26484794
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of glimepiride and atorvastatin
Trial: 26484794
Drug: Co-administered glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Co-administered glimepiride and atorvastatin (once daily for 20 weeks)
Trial: 26484794
Drug: Co-administered glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Co-administered glimepiride and atorvastatin
Trial: 17686442
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and pemetrexed combination therapy; standard treatment based on phase III-study evidence; initiation of therapy as early as possible.
Trial: 1729021
Drug: Intraoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intravenous heparin administration (1000 U bolus followed by 500 U every 30 minutes)
Trial: 1729021
Drug: Intraoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intravenous heparin administration (1000 U or 1500 U initial bolus followed by continuous heparin infusion)
Trial: 1729021
Drug: Intraoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intravenous heparin administration (1000 U bolus before hip dislocation, and 500 U bolus before femoral canal preparation)
Trial: 1729021
Drug: All heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All heparin groups combined
Trial: 1748537
Drug: Soft gelatin
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsule
Trial: 3729509
Drug: Hard gelatin
RxNorm normalized name: Hard Gelatin Capsule Shell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard gelatin capsule
Trial: 24262040
Drug: Warfarin (observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (observation group)
Trial: 24262040
Drug: No anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulant or antiplatelet medicine (control group)
Trial: 11060719
Drug: Protease inhibitors
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitors (e.g., amprenavir, indinavir, nelfinavir, ritonavir, saquinavir)
Trial: 11060719
Drug: Comparisons between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparisons between various licensed protease inhibitors
Trial: 11060719
Drug: Comparisons of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparisons of protease inhibitors to other classes of potent antiretroviral drugs
Trial: 11060719
Drug: Investigations with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigations with new protease inhibitors
Trial: 11060719
Drug: Investigations of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigations of protease inhibitor‐related toxicities
Trial: 11060719
Drug: Attempts at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attempts at simplifying current dosing regimens
Trial: 20205074
Drug: Olanzapine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10-20 mg QD)
Trial: 18555147
Drug: IV analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV analgesia with morphine (group B)
Trial: 16020142
Drug: Weekly sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly sessions of time‐limited theme‐based group psychotherapy for 6 months and 50 mg sildenafil citrate orally on demand
Trial: 16020142
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sildenafil citrate orally on demand for 6 months only
Trial: 16020142
Drug: Weekly sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly sessions of time‐limited theme‐based group psychotherapy for 6 months
Trial: 7595137
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g elemental calcium administered twice daily for 16 weeks
Trial: 7595137
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily for 16 weeks
Trial: 382153
Drug: Domperidone suppositories
RxNorm normalized name: domperidone Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone suppositories (30 mg)
Trial: 382153
Drug: Metoclopramide suppositories
RxNorm normalized name: metoclopramide Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide suppositories (10 mg)
Trial: 29701801
Drug: Low vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low vs. high adherence to antihypertensive medication
Trial: 22433221
Drug: Docetaxel (DTX)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (DTX) alone, 75 mg/m², 8 cycles, every 3 weeks
Trial: 22433221
Drug: Other treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other treatment groups (combined)
Trial: 19281469
Drug: tolterodine-ER (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine-ER (4 mg once daily)
Trial: 8066309
Drug: Verapamil (120-240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (120-240 mg/day)
Trial: 8066309
Drug: Nitrendipine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (10-20 mg/day)
Trial: 16116010
Drug: Femoral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral nerve block with 0.375% bupivacaine and 5 microg/mL epinephrine
Trial: 12364634
Drug: 5x300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5x300 mg 4162W94 (cohort 1 and 2)
Trial: 12364634
Drug: 5x100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5x100 mg 4162W94
Trial: 12364634
Drug: 5x300 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5x300 mg 4162W94
Trial: 28953776
Drug: Duloxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine + Acetylsalicylic Acid (100 mg)
Trial: 26364885
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with instructions about restricting food and fluid intake prior to radiotherapy simulation and treatment
Trial: 26364885
Drug: Patients without
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without instructions about restricting food and fluid intake prior to radiotherapy simulation and treatment
Trial: 21247431
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 5 mg/kg intravenous bolus injection, followed by 1.5 mg/kg/h continuous intravenous infusion until 3 hours after cessation of CPB
Trial: 9920070
Drug: 300 microg
RxNorm normalized name: Voglibose 300 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 microg DSG orally daily and 100 mg T enanthate, i.m., weekly
Trial: 9920070
Drug: 300 microg
RxNorm normalized name: Voglibose 300 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 microg DSG and 50 mg T enanthate
Trial: 9920070
Drug: 150 microg
RxNorm normalized name: Norgestrel 150 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 microg DSG and 100 mg T enanthate
Trial: 9920070
Drug: DSG (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSG (300 or 150 microg daily) alone for the first 3 weeks
Trial: 9920070
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of T enanthate (50 and 100 mg weekly)
Trial: 7703390
Drug: Subcutaneous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous recombinant erythropoietin (EPO)
Trial: 2641393
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg of triazolam administered sublingually
Trial: 2641393
Drug: Placebo (lactulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactulose solution 66.7%)
Trial: 19949
Drug: EHDP (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHDP (20 mg kg‐1 day‐1)
Trial: 31967979
Drug: Photobiostimulation (PBS)
RxNorm normalized name: PB-722
DrugBank: PB-722 (DB18447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiostimulation (PBS) after implant surgery
Trial: 31967979
Drug: Placebo (simulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (simulated photobiostimulation) after implant surgery
Trial: 31967979
Drug: Control (implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (implant surgery only)
Trial: 30146166
Drug: Monthly high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly high-dose vitamin D3 supplementation (100,000 IU)
Trial: 28595182
Drug: Dietary supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplements containing 125 mg green tea, 25 mg capsaicin and 50 mg ginger extracts
Trial: 21817821
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of statin
Trial: 19243207
Drug: Fed state
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fed state (CER 30 mg)
Trial: 19243207
Drug: Fasted state
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasted state (CER 30 mg)
Trial: 14715180
Drug: Azimilide dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
DrugBank: Azimilide (DB04957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azimilide dihydrochloride 35 mg
Trial: 14715180
Drug: Azimilide dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
DrugBank: Azimilide (DB04957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azimilide dihydrochloride 75 mg
Trial: 14715180
Drug: Azimilide dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
DrugBank: Azimilide (DB04957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azimilide dihydrochloride 125 mg
Trial: 11710578
Drug: Diclofenac after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac after oral administration
Trial: 11710578
Drug: Diclofenac after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac after rectal administration
Trial: 11710578
Drug: Ibuprofen (internal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (internal standard)
Trial: 30325567
Drug: FTC/TAF 200/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC/TAF 200/10 mg + darunavir (DRV) 800 mg + ritonavir (RTV) 100 mg (treatment A)
Trial: 30325567
Drug: FTC/TAF 200/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC/TAF 200/25 mg alone (treatment C)
Trial: 30325567
Drug: DRV/cobicistat (COBI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/cobicistat (COBI) 800/150 mg (treatment B)
Trial: 30325567
Drug: RTV and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTV and COBI boosting effects on TAF bioavailability
Trial: 28609567
Drug: BI 1021958
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1021958 (60 mg single dose)
Trial: 28609567
Drug: BI 1021958
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1021958 (≥60 mg single doses)
Trial: 28609567
Drug: BI 1021958
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1021958 (>40 mg multiple doses)
Trial: 21217530
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (UC) group maintained normal daily activities before TKA.
Trial: 19949272
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin K (K(1) and K(2)) supplementation
Trial: 19949272
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin K(2) supplementation
Trial: 17044661
Drug: Efonidipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efonidipine (40 mg)
Trial: 17044661
Drug: Nilvadipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine (2 mg)
Trial: 9490088
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy protocols
Trial: 2959900
Drug: Fenoterol plus
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol plus steroids
Trial: 2959900
Drug: Aminophylline, IV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline, IV, plus steroids and oral fenoterol
Trial: 2959900
Drug: Nebulized normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized normal saline solution
Trial: 29969742
Drug: uTLIF with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: uTLIF with PMMA augmentation
Trial: 27838680
Drug: Alternative antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative antimicrobial therapy
Trial: 21570642
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g casein hydrolysate
Trial: 21570642
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g casein hydrolysate
Trial: 21570642
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g casein hydrolysate (control)
Trial: 11101474
Drug: Fresh yogurt
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh yogurt (500 g/d for 15 days)
Trial: 11101474
Drug: Heated yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated yogurt (500 g/d for 15 days)
Trial: 8704064
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of 20 IU AVP
Trial: 8704064
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 1.5 IU AVP
Trial: 1288668
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physostigmine and deprenyl
Trial: 20370378
Drug: Rivoglitazone 1
RxNorm normalized name: rosiglitazone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoglitazone 1 mg